I
Israel Lowy
Researcher at Regeneron
Publications - 183
Citations - 16764
Israel Lowy is an academic researcher from Regeneron. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 36, co-authored 136 publications receiving 13932 citations. Previous affiliations of Israel Lowy include Medarex & Princeton University.
Papers
More filters
Journal ArticleDOI
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok,Harriet Kluger,Margaret K. Callahan,Michael A. Postow,Naiyer A. Rizvi,Alexander M. Lesokhin,Neil H. Segal,Charlotte E. Ariyan,Ruth-Ann Gordon,Kathleen Reed,Matthew M. Burke,Anne Caldwell,Stephanie Anne Kronenberg,Blessing Agunwamba,Xiaoling Zhang,Israel Lowy,Hector David Inzunza,William Feely,Christine Horak,Quan Hong,Alan J. Korman,Jon M. Wigginton,Ashok Kumar Gupta,Mario Sznol +23 more
TL;DR: Conurrent therapy with nivolumab and ipilimumab had a manageable safety profile and provided clinical activity that appears to be distinct from that in published data on monotherapy, with rapid and deep tumor regression in a substantial proportion of patients.
Journal ArticleDOI
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer,Charles G. Drake,Ira Wollner,John D. Powderly,Joel Picus,William H. Sharfman,Elizabeth Stankevich,Alice Pons,Theresa M. Salay,Tracee L. McMiller,Marta M. Gilson,Changyu Wang,Mark J. Selby,Janis M. Taube,Robert A. Anders,Lieping Chen,Alan J. Korman,Drew M. Pardoll,Israel Lowy,Suzanne L. Topalian +19 more
TL;DR: Blocking the PD-1 immune checkpoint with intermittent antibody dosing is well tolerated and associated with evidence of antitumor activity, and tumor cell surface B7-H1 expression appeared to correlate with the likelihood of response to treatment.
Journal ArticleDOI
Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma
Richard E. Royal,Catherine Levy,Keli Turner,Aarti Mathur,Marybeth Hughes,Udai S. Kammula,Richard M. Sherry,Suzanne L. Topalian,Suzanne L. Topalian,James Chih-Hsin Yang,Israel Lowy,Steven A. Rosenberg +11 more
TL;DR: A significant delayed response in one subject of this trial suggests that immunotherapeutic approaches to pancreas cancer deserve further exploration.
Journal ArticleDOI
PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma
Michael R. Migden,Danny Rischin,Chrysalyne D. Schmults,Alexander Guminski,Axel Hauschild,Karl D. Lewis,Christine H. Chung,Leonel Hernandez-Aya,Annette M. Lim,Anne Lynn S. Chang,Guilherme Rabinowits,Alesha A. Thai,Lara Dunn,Brett G.M. Hughes,Nikhil I. Khushalani,Badri Modi,Dirk Schadendorf,Bo Gao,Frank Seebach,Siyu Li,Jingjin Li,Melissa Mathias,Jocelyn Booth,Kosalai Kal Mohan,Elizabeth Stankevich,Hani M. Babiker,Irene Brana,Marta Gil-Martin,Jade Homsi,Melissa Lynne Johnson,Victor Moreno,Jiaxin Niu,Taofeek K. Owonikoko,Kyriakos P. Papadopoulos,George D. Yancopoulos,Israel Lowy,Matthew G. Fury +36 more
TL;DR: Among patients with advanced cutaneous squamous‐cell carcinoma, cemiplimab induced a response in approximately half the patients and was associated with adverse events that usually occur with immune checkpoint inhibitors.
Journal ArticleDOI
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck,Joseph A. Blansfield,Khoi Q. Tran,Andrew L. Feldman,Michael S. Hughes,Richard E. Royal,Udai S. Kammula,Suzanne L. Topalian,Richard M. Sherry,David E. Kleiner,Martha Quezado,Israel Lowy,Michael Yellin,S. A. Rosenberg,James Chih-Hsin Yang +14 more
TL;DR: CTLA4 seems to be a significant component of tolerance to tumor and in protection against immune mediated enterocolitis and these phenomena are significantly associated in cancer patients.